Cabozantinib (Cometriq) failed to significantly extend overall survival compared with prednisone as a treatment for men with metastatic castration-resistant prostate cancer.
- A Network of Your PeersView more >>
Most Popular Right Now
Dr Richard Michaelson and Kimberly Blackwell, MD discuss their decision-making processes when treating patients with metastatic HR+/HER2- breast cancer. View Now